| Pharma giant Shire could return £2bn to investors to bolster takeover defences |
Daily Mail, May 19, 2013 |
| Shire's shenanigans continue; guilty of 10 Code breaches |
Pharmatimes.com, May 17, 2013 |
| Scotland says yes to Shire's Elvanse but no to Pfizer's Xalkori |
Scrip, May 15, 2013 |
| Europe regulators not yet on board with adult ADHD due to concerns regarding diagnosis methods |
FT.com, May 9, 2013 |
| Shire Wins Block of Actavis’s Lialda Copy Until 2020 |
bloomberg.com, May 9, 2013 |
| Shire scores patent success with bowel disease drug |
FT.com, May 8, 2013 |
| Bid talk returns to Shire as FTSE 100 hits another five and a half year high |
guardian.co.uk, May 8, 2013 |
| Shire: – rarity value |
FT.com, May 3, 2013 |
| Shire slumps after lowering revenue outlook |
AP News, May 2, 2013 |
| New CEO, new structure at Shire as 1Q slips |
Scrip, May 2, 2013 |
| Shire 1Q US GAAP Op. Income -56%, Backs FY View; Unveils New Structure |
WSJ.com, May 2, 2013 |
| Shire Cuts Full-Year Sales Forecast as Revenue Misses Estimates |
bloomberg.com, May 2, 2013 |
| Dane who won't make a drama out of a drugs giant |
The Sunday Times, Apr 28, 2013 |
| Shire Settles Suit With Actavis to Delay Intuniv Copy |
bloomberg.com, Apr 25, 2013 |
| Orphan Drug Prices Under Siege in Austerity-Minded Europe |
bloomberg.com, Apr 7, 2013 |
| Shire to Buy Eye-Drug Maker SARcode for $160 Million |
bloomberg.com, Mar 25, 2013 |
| Shire Buys Premacure for Blindness-Preventing Drug in Infants |
bloomberg.com, Mar 12, 2013 |
| Shire’s New Chief Said to Eye Two to Three Acquisitions |
bloomberg.com, Feb 20, 2013 |
| Shire Falls Most Since June on Adderall XR Competition |
bloomberg.com, Feb 14, 2013 |
| Adult demand for ADD drug lifts Shire |
FT.com, Feb 14, 2013 |
| Shire to Forest on Deal List for AstraZeneca: Real M&A |
bloomberg.com, Feb 12, 2013 |
